Biotech Valuations

Santhera Pharmaceuticals has staked its commercial future almost entirely on vamorolone, a steroid alternative for Duchenne Muscular Dystrophy. With no meaningful fallback revenue, analysts flag the Swiss biotech as a high-concentration pipeline play carrying catastrophic downside if the asset stumbles. Here is what market investors weighing rare disease exposure should understand.